-DOCSTART- -X- O
Changes -X- _ O
in -X- _ O
lifestyle -X- _ O
and -X- _ O
environmental -X- _ O
conditions -X- _ O
give -X- _ O
rise -X- _ O
to -X- _ O
an -X- _ O
increasing -X- _ O
prevalence -X- _ O
of -X- _ O
liver -X- _ B-Patient
and -X- _ I-Patient
lung -X- _ I-Patient
fibrosis -X- _ I-Patient
, -X- _ O
and -X- _ O
both -X- _ O
have -X- _ O
a -X- _ O
poor -X- _ O
prognosis. -X- _ O
Promising -X- _ O
results -X- _ O
have -X- _ O
been -X- _ O
reported -X- _ O
for -X- _ O
recombinant -X- _ B-Intervention
angiotensin-converting -X- _ I-Intervention
enzyme -X- _ I-Intervention
2 -X- _ I-Intervention
( -X- _ I-Intervention
ACE2 -X- _ I-Intervention
) -X- _ I-Intervention
protein -X- _ I-Intervention
administration -X- _ I-Intervention
in -X- _ O
experimental -X- _ O
liver -X- _ B-Patient
and -X- _ I-Patient
lung -X- _ I-Patient
fibrosis. -X- _ I-Patient
However -X- _ O
, -X- _ O
the -X- _ O
full -X- _ O
potential -X- _ O
of -X- _ O
ACE2 -X- _ O
may -X- _ O
be -X- _ O
achieved -X- _ O
by -X- _ O
localized -X- _ O
translation -X- _ O
of -X- _ O
a -X- _ O
membrane-anchored -X- _ O
form. -X- _ O
For -X- _ O
this -X- _ O
purpose -X- _ O
, -X- _ O
we -X- _ O
advanced -X- _ O
the -X- _ O
latest -X- _ O
RNA -X- _ O
technology -X- _ O
for -X- _ O
liver- -X- _ O
and -X- _ O
lung-targeted -X- _ O
ACE2 -X- _ O
translation. -X- _ O
We -X- _ O
demonstrated -X- _ O
in -X- _ O
vitro -X- _ O
that -X- _ O
transfection -X- _ B-Intervention
with -X- _ I-Intervention
ACE2 -X- _ I-Intervention
chemically -X- _ I-Intervention
modified -X- _ I-Intervention
messenger -X- _ I-Intervention
RNA -X- _ I-Intervention
( -X- _ I-Intervention
cmRNA -X- _ I-Intervention
) -X- _ I-Intervention
leads -X- _ I-Intervention
to -X- _ I-Intervention
robust -X- _ I-Intervention
translation -X- _ I-Intervention
of -X- _ I-Intervention
fully -X- _ I-Intervention
matured -X- _ I-Intervention
, -X- _ I-Intervention
membrane-anchored -X- _ I-Intervention
ACE2 -X- _ I-Intervention
protein. -X- _ I-Intervention
In -X- _ O
a -X- _ O
second -X- _ O
step -X- _ O
, -X- _ O
we -X- _ O
designed -X- _ O
eight -X- _ O
modified -X- _ O
ACE2 -X- _ O
cmRNA -X- _ O
sequences -X- _ O
and -X- _ O
identified -X- _ O
a -X- _ O
lead -X- _ O
sequence -X- _ O
for -X- _ O
in -X- _ O
vivo -X- _ O
application. -X- _ O
Finally -X- _ O
, -X- _ O
formulation -X- _ O
of -X- _ O
this -X- _ O
ACE2 -X- _ O
cmRNA -X- _ O
in -X- _ O
tailor-made -X- _ O
lipidoid -X- _ O
nanoparticles -X- _ O
and -X- _ O
in -X- _ O
lipid -X- _ O
nanoparticles -X- _ O
led -X- _ O
to -X- _ O
liver- -X- _ B-Outcome
and -X- _ I-Outcome
lung-targeted -X- _ I-Outcome
translation -X- _ I-Outcome
of -X- _ I-Outcome
significant -X- _ I-Outcome
amounts -X- _ I-Outcome
of -X- _ I-Outcome
ACE2 -X- _ I-Outcome
protein -X- _ I-Outcome
, -X- _ O
respectively. -X- _ O
In -X- _ O
summary -X- _ O
, -X- _ O
we -X- _ O
provide -X- _ O
evidence -X- _ O
that -X- _ O
RNA -X- _ O
transcript -X- _ O
therapy -X- _ O
( -X- _ O
RTT -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
promising -X- _ O
approach -X- _ O
for -X- _ O
ACE2-based -X- _ O
treatment -X- _ O
of -X- _ O
liver -X- _ B-Patient
and -X- _ I-Patient
lung -X- _ I-Patient
fibrosis -X- _ I-Patient
to -X- _ O
be -X- _ O
tested -X- _ O
in -X- _ O
fibrotic -X- _ O
disease -X- _ O
models -X- _ O
. -X- _ O

